Protumor immunity and breast cancer development by LM Coussens
BioMed Central
Page 1 of 1
(page number not for citation purposes)
BMC Proceedings
Open AccessMeeting abstract
Protumor immunity and breast cancer development
LM Coussens
Address: Department of Pathology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, 
CA 94143, USA
Email: LM Coussens - Lisa.coussens@ucsf.edu
For decades, it was generally accepted that leukocytic infil-
trations in tumors represented a failed attempt of the
immune system to eradicate damaged cells. While indeed
some aspects of failed anti-tumor immunity exist, what
we now appreciate is the fact that multiple protumor
immune programs are instead co-opted by nascent
tumors, and in so doing significantly enhance tumor
development, including breast cancer. Based upon our
evaluation of human clinical specimens revealing signifi-
cant infiltration of breast tumor tissue by both T lym-
phocytes and macrophages, we asked the question as to
whether adaptive immunity was perhaps enhancing pro-
tumor properties of macrophages and thereby potentiat-
ing breast carcinogenesis. Utilizing the MMTV-PyMT
mouse model of mammary carcinogenesis, CD4+ T cell-
deficient mice, and an ex vivo three-dimensional organoid
co-culture model, we revealed a tumor-promoting role for
TH2-CD4+ T effector cells that elicit pro-tumor, as opposed
to cytotoxic, bioactivities of tumor-associated macro-
phages (TAMs) and enhancement of pro-metastatic epi-
dermal growth factor (EGF) receptor signaling programs
in malignant mammary epithelial cells. These novel find-
ings provide a mechanism explaining how TH2-activated
TAMs achieve HIGH level expression of EGF necessary for
inducing survival, invasive growth and metastatic pro-
grams in malignant cells, and together indicate that anti-
tumor acquired immunity, mediated by CD4+ T lym-
phocytes are usurped in pro-tumor microenvironments
and instead promote cancer by engaging cellular compo-
nents of the innate immune system, and identifies new
cellular targets, namely TH2-polarized CD4+ T lym-
phocytes, for anti-cancer therapy.
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